½ÃÀ庸°í¼­
»óǰÄÚµå
1532976

Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀå - ¿¹Ãø(2024-2029³â)

Polymer Excipients Market - Forecasts from 2024 to 2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Knowledge Sourcing Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 141 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2029³â)¿¡ CAGR 4.27%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀåÀº ÇÕ¼º Æú¸®¸Ó ¶Ç´Â õ¿¬ Æú¸®¸Ó¿¡¼­ À¯·¡µÈ Á¦¾à Á¦Á¦¿ë ¼ººÐÀÇ ±Þ¼ÓÇÑ ½ÃÀå °³Ã´ ºÐ¾ß·Î Á¤ÀÇµÉ ¼ö ÀÖ½À´Ï´Ù. ¾à¹° Àü´Þ ½Ã½ºÅÛ¿¡¼­ Áß¿äÇÑ ºÎÇüÁ¦´Â ¾àÁ¦ÀÇ ¾ÈÁ¤¼º ¹× È¿´ÉÀ» Çâ»ó½Ãŵ´Ï´Ù.

¾à¹° Àü´Þ ½Ã½ºÅÛ¿¡¼­ Æú¸®¸Ó ºÎÇüÁ¦ÀÇ À¯¿¬ÇÑ »ç¿ë¿¡´Â ¹æÃâ Á¦¾î Á¦Çü, ĸ½¶È­, Á¤Á¦ ÄÚÆÃ, ¿ëÇØ¼ºÀ» Çâ»ó½Ã۱â À§ÇÑ »ý¹° Á¦Á¦¿ÍÀÇ ÄÁÁê°ÔÀÌ¼Ç µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀǾà¿ë À×Å© Á¦Á¶, Âø»öÁ¦ ¹× ¾È·á Áغñ, È­Àåǰ, °í±Þ »óó Ä¡·á¿¡µµ »ç¿ëµË´Ï´Ù. ±× ¹è°æ¿¡´Â ¾à¹°Àü´ÞÀÇ ½Å±â¼ú¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁö°í, Áúº´ ¹ß»ý·üÀÇ »ó½Â, ȯÀÚÀÇ ÄÄÇöóÀ̾𽺠ÁؼöÀÇ Ã¶Àú µîÀÌ ÀÖ½À´Ï´Ù.

  • Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀåÀº »ó½Â °æÇâÀÌ ÀÖÀ¸¸ç ±× ¹è°æ¿¡´Â ¸î °¡Áö ÀÌÀ¯°¡ ÀÖ½À´Ï´Ù. TSWI´Â Å« ¼ºÀå ¿äÀÎ Áß Çϳª·Î¼­ »õ·Î¿î ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼¼°èÀÇ ¿ä±¸¸¦ ²Å°í ÀÖ½À´Ï´Ù. Á¦¾à »ê¾÷¿¡¼­ÀÇ Áøº¸µÈ Ä¡·á¹ýÀÌ Áõ°¡ÇÔ¿¡ µû¶ó, ¾à¹°ÀÇ ¾ÈÁ¤¼º, »ýüÀÌ¿ë·ü ¹× È¿´É¿¡ À־ ´õ ³ªÀº ¼º´ÉÀ» °®´Â ºÎÇüÁ¦¿¡ ´ëÇÑ ¿ä±¸µµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹æÃâ Á¦¾î ½Ã½ºÅÛ, ĸ½¶È­, »ý¹°ÇÐÀû Á¦Á¦¿ÍÀÇ ÄÁÁê°ÔÀ̼ǿ¡ °ü¿©ÇÏ´Â Æú¸®¸Ó ºÎÇüÁ¦´Â ÃÖ÷´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛÀ» ±¸ÃàÇϴµ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿ä±¸´Â ¸¸¼º Áúȯ Áõ°¡¿Í ȯÀÚÀÇ ¾îµåÈ÷¾î·±½º °­È­ÀÇ Çʿ伺¿¡ ÀÇÇØ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
  • ½ÃÀå ¼ºÀåÀ» È®´ëÇÏ´Â ¶Ç ´Ù¸¥ ¿äÀÎÀº ¼¼°èÀûÀ¸·Î Á¦³×¸¯ ÀǾàǰÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â °ÍÀÔ´Ï´Ù. ½ÃÀåÀº Á¦³×¸¯ ÀǾàǰÀÇ ÁøÀÔÀ» ¸ñ°ÝÇϰí ÀÖÀ¸¸ç, ±× ´ëºÎºÐÀº ƯÇã º¸È£ÀÇ ÇØÁö·Î ÀÎÇØ ÀÌÀü¿¡´Â ºê·£µå ÀǾàǰ¸¸ÀÇ ¿µ¿ªÀ̾ú½À´Ï´Ù. µû¶ó¼­ ºÎÇüÁ¦´Â ÀÏ¹Ý ÀǾàǰÀÇ Ç°Áú, ¾ÈÀü¼º ¹× È¿´ÉÀ» Áö¿øÇÕ´Ï´Ù. ÀÌ Á¡¿¡¼­ Æú¸®¸Ó ºÎÇüÁ¦´Â Á¦³×¸¯ ÀǾàǰ¿¡ Æ÷ÇÔµÈ Ä¡·áÁ¦ÀÇ È­ÇÐÀû ¹× ¹°¸®Àû ¾ÈÁ¤¼º, µû¶ó¼­ È¿´ÉÀ» ³ôÀÏ ¼ö ÀÖ´Â Áß¿äÇÑ Á¦Çü ¼ººÐÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¾ÕÀ¸·Îµµ °è¼ÓµÉ °ÍÀ¸·Î »ý°¢µÇ¸ç, Æú¸®¸Ó ºÎÇüÁ¦¿¡ ´ëÇÑ ¿ä±¸´Â ´õ¿í ³ô¾ÆÁö°í Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÀÚ±ØÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀåÀÇ ºÎ¹® ºÐ¼® :

  • Æú¸®ºñ´ÒÇǷѸ®µ· ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ºÐ¾ßÀÏ °ÍÀÔ´Ï´Ù.

¸ðµç Æú¸®¸Ó ºÎÇüÁ¦ Áß¿¡¼­ Æú¸®ºñ´ÒÇǷѸ®µ·(PVP) ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È ƯÁ¤ ½ÃÀå¿¡¼­ °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ºÎ¹®À¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ´Â PVP°¡ »ó´çÈ÷ Ư¼öÇÑ ¿ëµµ¿Í Ư¼ºÀ» °¡Áö°í ÀÖ¾î Á¦¾à ¾÷°è¿¡¼­ PVPÀÇ »ç¿ë·®ÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. PVP·Î ½Äº°µÇ´Â Æ÷ºñµ·Àº ÇÕ¼º Æú¸®¸ÓÀ̸ç, ´Ù¾çÇÑ À¯ÇüÀÇ Á¦Çü¿¡¼­ ÇʼöÀûÀÎ ºÎÇüÁ¦·Î °£Áֵ˴ϴÙ. ü³» Èí¼öÀÇ ¿ëÀ̼º, ¿ëÇØ¼º, Çʸ§ Çü¼º¼º, »ýü ºÒÅõ°ú¼º µîÀÇ Æ¯Áú¿¡ ÀÇÇØ ¾÷°è¿¡¼­ ÀαⰡ Àִ ÷°¡Á¦°¡ µÇ°í ÀÖ½À´Ï´Ù.

PVP´Â ÀϹÝÀûÀ¸·Î Á¤Á¦, ĸ½¶, ½Ã·´, »ì±ÕÁ¦, ¼Òµ¶Á¦, ÁÖ»çÁ¦ÀÇ Á¦Á¶¿¡ »ç¿ëµË´Ï´Ù. ÀǾà Á¦Á¦ÀÇ ¹ÙÀδõ, ºØÇØÁ¦, ¿ëÇØÁ¦, ¾ÈÁ¤Á¦·Î¼­ ±â´ÉÇϰí, ÀǾàǰÀÇ ¾ÈÁ¤¼º, »ýüÀÌ¿ë·ü, È¿´ÉÀ» Çâ»ó½ÃŰ´Â Áß¿äÇÑ º¸Á¶Á¦·Î¼­ ÀÛ¿ëÇÕ´Ï´Ù.

PVPÀÇ ¿ä±¸´Â ¸¸¼º Áúȯ°ú °°Àº °Ç°­ ÇÕº´Áõ ¹× ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ±â¼ú Çâ»óÀ¸·Î ÃÖ±Ù ¸î ³âµ¿¾È Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¦¾à »ê¾÷ÀÌ Áøº¸ÇÏ°í º¸´Ù ±¸Ã¼ÀûÀ̰í È¿°úÀûÀÎ ÀǾàǰÀÌ °³¹ßµÊ¿¡ µû¶ó ÀǾàǰÀÇ È¿À²À» Çâ»ó½ÃŰ´Â ¿ªÇÒÀ» ÇÏ´Â ºÎÇüÁ¦ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ȯÀÚ ¼­ºñ½ºÀÇ ÀϹÝÈ­¿Í ¼øÈ¯±â Ä¡·á ºÐ¾ß¿¡¼­ ¸¸¼º Áúȯ °ü¸®¿¡ º¸´Ù °íµµ·Î °³º°È­µÈ Á¢±Ù¹ýÀÇ Çʿ伺À¸·Î ÀÎÇØ ´Ù¾çÇÑ À¯ÇüÀÇ ¾à¹° Á¦Çü¿¡ ÀûÀÀÇÒ ¼ö ÀÖ´Â PVP´Â ÀÌ·¯ÇÑ ¹Ì·¡ÀÇ ¿ä±¸¿¡ ÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶¿Í COVID-19 ¹é½Å °³¹ß µîÀÇ »õ·Î¿î °æÇâµµ PVP ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çʼö ÀǾàǰÀÇ Á¦ÇüÈ­ ¹× Á¦Á¶¿¡ À־ÀÇ ºÎÇüÁ¦ÀÇ ¿ªÇÒÀº ÀÌ ÆÒµ¥¹Í µ¿¾È, º¸´Ù °­Á¶µÇ¾î, °á°úÀûÀ¸·Î, ½ÃÀå¿¡¼­ Å« ¼º°ú¸¦ ¿Ã¸®°í ÀÖ½À´Ï´Ù.

  • ¹ÙÀδõ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ºÎ¹®À¸·Î °£Áֵ˴ϴÙ.

À§ÀÇ ºÐ¼®Àº ¿¹Ãø ±â°£ µ¿¾È ¼¼°èÀÇ Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀå¿¡¼­ ¹ÙÀδõ ºÎ¹®ÀÌ °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °¡´É¼ºÀÌ ³ô´Ù´Â °á·ÐÀ» ³»·È½À´Ï´Ù. ÀÌ´Â ÀǾàǰÀÇ ¹°¸®Àû ¹× È­ÇÐÀû Ư¼ºÀ» Çâ»ó½ÃŰ´Â µ¥ »ç¿ëµÇ´Â ¹ÙÀδõ ½ÃÀå ±Ô¸ð°¡ È®´ëµÇ´Â °Í°ú °ü·ÃÀÌ ÀÖ´Ù°í »ý°¢µË´Ï´Ù. Æú¸®¸Ó ºÎÇüÁ¦´Â ¹ÙÀδõ Ä«Å×°í¸®¿¡ ¼ÓÇϸç Á¤Á¦¿Í ĸ½¶À» Æ÷ÇÔÇÑ °íÇü Á¦Á¦ÀÇ Áغñ¿¡ »ç¿ëµË´Ï´Ù. ¹ÙÀδõ´Â ź·Â¼º, ÀÎÀå °­µµ ¹× ¹ÙÀεù Á¶¼ºÀ» Á¦Çü¿¡ Àü´ÞÇÏ°í º¸Á¸ ¶Ç´Â ¼ö¼Û Áß¿¡ ¹ÙÀεù »óŸ¦ À¯ÁöÇϸç ǰÁúÀ» À¯ÁöÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. Áï, ¹ÙÀδõ´Â ¿ë¾×ÀÇ ÇüÅ·Π¶Ç´Â ¾à¹°ÀÇ Æ¯Á¤ Á¦Çü¿¡ ´ëÇÑ Á÷Á¢ ¾ÐÃàÀ» À§ÇÑ ºÐ¸»·Î äÅà µÉ ¼ö ÀÖ½À´Ï´Ù.

Á¦¾à »ê¾÷¿¡¼­ ¹ÙÀδõÀÇ »ç¿ë·® Áõ°¡´Â ¸¸¼º Áúȯ Áõ°¡¿Í ¾à¹° Àü´Þ ¹æ¹ýÀÇ °³¼±À¸·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. Çö´ë Á¦¾à »ê¾÷Àº °íµµ·Î Àü¹®È­µÈ ÀǾàǰÀÇ Á¦Á¶¸¦ Ư¡À¸·Î Çϸç, ÀÌ·¯ÇÑ ÀǾàǰÀº ¼º´ÉÀ» ´õ¿í Çâ»ó½Ã۱â À§ÇØ È¿°úÀûÀÎ ºÎÇüÁ¦¸¦ ÇÊ¿ä·Î ÇÕ´Ï´Ù. Á¦Á¦ÀÇ ¹°¸®Àû ¹× È­ÇÐÀû Ư¼ºÀ» Çâ»ó½ÃÅ´À¸·Î½á ¹ÙÀδõ´Â ÀÌ·¯ÇÑ ¼ö¿ä Áõ°¡¿¡ È¿°úÀûÀ¸·Î ´ëÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À ÀǾàǰÀÇ ¼¼°è µ¿Çâ°ú COVID-19 ¹é½ÅÀÇ Çʿ伺Àº ¹ÙÀδõ ¼Òºñ Áõ°¡¸¦ ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. COVID-19 À§±â´Â ÀǾàǰÀÇ Á¦ÇüÈ­¿Í ½ÃÀå °³Ã´¿¡ »ç¿ëµÇ´Â ºÎÇüÁ¦¿¡ ÃÊÁ¡À» ¸ÂÃß°í ½ÃÀåÀÇ Å« ÁøÀüÀ» ÃËÁøÇß½À´Ï´Ù.

  • ¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀº Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº ¸î °¡Áö Áß¿äÇÑ ¿ä¼Ò¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±× ÁÖµÈ ÀÌÀ¯´Â ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ Áö¼ÓÀûÀ¸·Î °³Ã´µÇ°í ÀÖ´Â ÀÇ¾à ½ÃÀå¿¡¼­ Æú¸®¸Ó ºÎÇüÁ¦ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â °ÍÀÔ´Ï´Ù. Áß±¹°ú ÀεµÀÇ »ç·Ê¸¦ º¸¸é ¸¸¼º Áúȯ Áõ°¡, Àα¸ °í·ÉÈ­, °Ç°­ °ü¸® Á¢±Ù¼º Áõ°¡·Î ÀÎÇØ ÀǾàǰ »ý»ê ¹× ¼Òºñ¸¦ ÅëÇØ ÀǾàǰ ÃßÃâ¿¡ ´ëÇÑ °æ»ç¿¡ º¯È­°¡ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù. ÀǾàǰ Á¦Á¶ »ê¾÷ÀÌ ¹ßÀüÇÔ¿¡ µû¶ó, ÀǾàǰÀÇ Á¦ÇüÈ­¿¡ ÇʼöÀûÀÎ Æú¸®¸Ó ºÎÇüÁ¦ÀÇ »ç¿ëµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀÌ Áö¿ª¿¡¼­´Â Á¦³×¸¯ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ôÀº ¼ºÀåÀ» º¸ÀÌ¸ç Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¿À´Ã³¯ÀÇ Á¦³×¸¯ ÀǾàǰ Á¦Á¶¾÷ü´Â Á¦Ç°À» ¾ÈÀüÇϰí È¿°úÀûÀ¸·Î ¸¸µé±â À§ÇØ ´ëºÎºÐ ºÎÇüÁ¦¿¡ ÀÇÁ¸ÇÕ´Ï´Ù. Æú¸®¸Ó ºÎÇüÁ¦´Â Á¦³×¸¯ ÀǾàǰÀÇ ¾ÈÁ¤¼º°ú »ýüÀÌ¿ë·üÀ» Çâ»ó½ÃŰ´Â ÀÌÁ¡ÀÌ Àֱ⠶§¹®¿¡ ÀÌ ´ë±Ô¸ð ½ÅÈï ½ÃÀå¿¡¼­µµ ¹Þ¾Æµé¿©Áö°í ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ »õ·Î¿î ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ Áøº¸¿Í ÇÔ²², °³ÀÎÈ­µÈ ¾à¹° ¿ä¹ýÀÇ µ¿Çâ Áõ°¡´Â Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀåÀ» ¹Ð¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù. Æú¸®¸Ó ºÎÇüÁ¦´Â Á¦ÇüÀÇ ±¸¼º¿¡ À¯¿¬¼ºÀÌ Àֱ⠶§¹®¿¡ ÀÌ Áö¿ªÀÇ ±âÁ¸ ¹× ½ÅÈï ½ÃÀåÀÇ ¿ä±¸¸¦ ÃæÁ·½Ãų °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

°Ô´Ù°¡ ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ ¹ÙÀÌ¿À ÀǾàǰ ºÐ¾ßÀÇ ¼ºÀå°ú COVID-19 ¹é½ÅÀÇ ¹ß¸íÀº ±¸¸í ÀǾàǰ Á¦Á¶¿¡¼­ ºÎÇüÁ¦ÀÇ ¿ëµµ¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ´Â »ý»êÀÚ°¡ °è¼Ó ¼ºÀåÇÏ´Â ½ÃÀå¿¡ ÀûÀÀÇϱâ À§ÇØ Á¶»ç¿¡ ´ëÇÑ °ü½ÉÀ» È®´ëÇϱâ À§ÇØ Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀå¿¡ ¸î °¡Áö °³¼±À» °¡Á®¿Ã ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀ¸·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀº ±Þ¼ºÀåÇÏ´Â Á¦¾à »ê¾÷, Á¦³×¸¯ ÀǾàǰ Áõ°¡, °³ÀÎÈ­µÈ ÀǾàǰ, »õ·Î¿î ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀüÀ¸·Î ¿¹Ãø ±â°£ ³»¿¡ Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù.

Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀåÀº ´ÙÀ½°ú °°ÀÌ ºÐ·ùµÇ°í ºÐ¼®µË´Ï´Ù.

Á¦Ç° À¯Çüº°

  • Æú¸®ºñ´ÒÇǷѸ®µ·
  • Æú¸®¿¡Æ¿·»±Û¸®ÄÝ
  • ÀüºÐ
  • ¹Ì°áÁ¤ ¼¿·ê·Î¿À½º(MCC)
  • ¿¡Æ¿ ¹× ¸ÞÆ¿¼¿·ê·Î¿À½º
  • È÷µå·Ï½ÃÇÁ·ÎÆÄÀÏ¸ÞÆ¿¼¿·ê·Î¿À½º(HPMC)
  • ±âŸ

¿ëµµº°

  • ¹ÙÀδõ
  • Á¡µµ Á¶Á¤Á¦
  • ÄÚÆÃ
  • Çâ·á
  • º¸Á¸·á
  • Âø»ö·á
  • °¨¹Ì·á
  • ±âŸ

Áö¿ªº°

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ³²¹Ì
  • ºê¶óÁú
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÇÁ¶û½º
  • ÀÌÅ»¸®¾Æ
  • ½ºÆäÀÎ
  • ±âŸ À¯·´
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • Àεµ³×½Ã¾Æ
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • ½ÃÀå °³¿ä
  • ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»ç ¹üÀ§
  • ½ÃÀå ¼¼ºÐÈ­
  • ÅëÈ­
  • ÀüÁ¦Á¶°Ç
  • ±âÁØ³â ¹× ¿¹Ãø³âÀÇ Å¸ÀÓ¶óÀÎ
  • ÀÌÇØ °ü°èÀÚÀÇ ÁÖ¿ä ÀÌÁ¡

Á¦2Àå Á¶»ç ¹æ¹ý

  • Á¶»ç µðÀÚÀÎ
  • Á¶»ç °úÁ¤

Á¦3Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¾Ö³Î¸®½ºÆ® º¸±â

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀåÇÏ´Â Á¦¾à ¾÷°è
    • ÄÚÆÃ ¿ëµµ·ÎºÎÅÍÀÇ Æú¸®¸Ó ºÎÇüÁ¦ ¼ö¿ä Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±ÔÁ¦±â°ü¿¡ ÀÇÇÑ ¾ö°ÝÇÑ ±ÔÄ¢
    • Á¦Ç°ÀÇ ¿ä±¸ ǰÁúÀ» ¸¸Á·½Ã۱â À§ÇÑ ¹è·Á
    • ´ëüǰÀ¸·ÎºÎÅÍÀÇ À§Çù
  • Porter's Five Forces ºÐ¼®
  • ¾÷°è ¹ë·ùüÀÎ ºÐ¼®

Á¦5Àå Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀå : Á¦Ç° À¯Çüº°

  • ¼­¹®
  • Æú¸®ºñ´ÒÇǷѸ®µ·
  • Æú¸®¿¡Æ¿·»±Û¸®ÄÝ
  • ÀüºÐ
  • ¹Ì°áÁ¤ ¼¿·ê·Î¿À½º(MCC)
  • ¿¡Æ¿ ¹× ¸ÞÆ¿¼¿·ê·Î¿À½º
  • È÷µå·Ï½ÃÇÁ·ÎÆÄÀÏ¸ÞÆ¿¼¿·ê·Î¿À½º(HPMC)
  • ±âŸ

Á¦6Àå Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀå : ¿ëµµº°

  • ¼­¹®
  • ¹ÙÀδõ
  • Á¡µµ Á¶Á¤Á¦
  • ÄÚÆÃ
  • Çâ·á
  • ¹æºÎÁ¦
  • Âø»öÁ¦
  • °¨¹Ì·á
  • ±âŸ

Á¦7Àå Æú¸®¸Ó ºÎÇüÁ¦ ½ÃÀå : Áö¿ªº°

  • ¼¼°è °³¿ä
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • ³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ³²¹Ì
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ´ë¸¸
    • ű¹
    • Àεµ³×½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦8Àå °æÀï ȯ°æ ¹× ºÐ¼®

  • ÁÖ¿ä ±â¾÷ ¹× Àü·« ºÐ¼®
  • ½ÃÀå Á¡À¯À² ºÐ¼®
  • ÇÕº´, Àμö, ÇÕÀÇ ¹× Çù¾÷
  • °æÀï ´ë½Ãº¸µå

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • ABITEC
  • ADM
  • Ashland
  • BASF SE
  • Cargill, Incorporated.
  • Colorcon
  • Croda International Plc
  • DFE Pharma
  • Dow
  • DuPont
  • Eastman Chemical Company
  • Evonik Industries AG
  • FINAR LIMITED
  • JRS PHARMA
  • Kerry Inc.
  • Roquette Freres
  • The Lubrizol Corporation
AJY 24.09.06

The polymer excipients market is expected to grow at a CAGR of 4.27% during the forecast period (2024-2029).

The polymer excipients market can be defined as the rapidly developing field of components for pharmaceutical formulations originating from synthetic and natural polymers. The following are some of the excipients that are important in drug delivery systems; they improve the stability and efficacy of pharmaceutical products.

The flexible use of polymer excipients in drug delivery systems includes controlled release formulations, encapsulation, coating of tablets, and conjugation to biologics to improve solubility. They are also employed in the production of pharmaceutical inks, the preparation of colorants and pigments, cosmetics, and advanced wound care items. This is due to the enhanced need for new technologies in drug delivery, the rising incidence of diseases, and strict patient compliance.

  • The polymer excipients market is on an upward trend and there are several reasons that have attributed to the above trend. TSWI has identified one of the large growth factors as being the global need for new drug delivery systems. With the increase of advanced therapies in the pharmaceutical industry, so is the requirement for excipients with better performance in stability, bioavailability, and effectiveness of the drugs. Polymer excipients that are involved in the controlled release systems, encapsulation, and conjugation to the biologics are critical to incorporate in creating state-of-the-art drug delivery systems. This need is heightened by the increasing incidence of chronic ailments and the necessity to enhance adherence among patients.
  • Another avenue for expanding the firm's growth is the increasing use of generic medicines globally. The market is witnessing the entry of generics, many of which were earlier solely in the domain of branded drugs due to the expiry of patent protection. As such, excipients are the backbone of generic drugs' quality, safety, and efficacy. In this regard, polymer excipients are significant formulating components that can enhance the chemical and physical stability and, therefore, the efficacy of the therapeutic agents contained in generic products. It is believed that this trend will persist in future years, and the need for polymer excipients will be even higher, stimulating the polymer excipients market's growth.

POLYMER EXCIPIENTS MARKET SEGMENT ANALYSIS:

  • The Polyvinylpyrrolidone segment will likely be the fastest-growing segment during the forecast period.

Out of all the polymer excipients, the polyvinylpyrrolidone (PVP) segment is predicted to be the fastest-growing segment in the identified market for the duration of the forecast year. This can be attributed to the rise in the usage of PVP in the pharmaceutical industry because of its fairly special uses and characteristics. Povidone, which is identified as PVP, is a synthetic polymer that is regarded as an essential excipient in different types of formulations. Ease of absorption into the body, as well as such qualities as solubility and film-forming properties and the organism's impermeability - all these make it a popular additive in the industry.

PVP is usually used in the production of tablets, capsules, syrup, sterilization, disinfection, and injection. It functions as a binder, disintegrant, solubilizer, and stabilizer in drug formulations, thus acting as an important adjuvant in improving the stability, bioavailability, and effectiveness of pharmaceuticals.

The need for PVP has risen in recent years due to health complications such as chronic diseases and enhancements of techniques in drug delivery systems. With the progression of the pharmaceutical industry and the creation of more specific, effective medication the need for excipients rises as they play the role of improving drug efficiency. The generalization of patient services and the need for more sophisticated and individualized approaches in the management of chronic disease in the field of cardiovascular therapy allows PVP, which can be adapted to different types of drug formulations, to meet these future needs. The new tendencies, such as the biopharmaceuticals production and the COVID-19 vaccine development, also create demand for PVP. The role of excipients as ingredients in the formulation and manufacturing of such essential drugs has been more emphasized during this pandemic, and as a result, great achievements have been made on the market.

  • The Binders segment will likely be the fastest-growing segment during the forecast period.

Based on the above analysis, it can be concluded that the binders segment is likely to grow at the fastest rate in the global polymer excipients market over the forecasting period. This may be related to the rising market size for binders in the pharma, which is used to enhance the physical and chemical characteristics of drug products. Polymer excipients belong to the category of binders and are employed in the preparation of solid dosage forms including tablets and capsules. They assist in conveying elasticity, tensile strength, and a bonded composition to the formulation of the product to stay united and preserve its quality during storage or transport. This means that binders can be employed in solution form or as a powder for direct compaction for that specific formulation of drugs.

The rising usage of binders in the pharmaceutical industry is attributed to the rise in chronic ailments and improved drug delivery methods. The modern pharmaceutical industry is characterized by the production of highly specialized medicines, which require effective excipients to further boost their performance. By enhancing the physical and chemical characteristics of drug formulations, binders can effectively address this increasing demand.

The global trend of biopharmaceuticals and the need for the COVID-19 vaccine have caused increased binders consumption. The COVID-19 crisis has brought focus to excipients used in medicinal formulation and development, catalyzing significant market progress.

  • The Asia Pacific region will dominate the polymer excipients market during the forecast period.

The Asia Pacific region is expected to dominate the polymer excipients market during the forecast period, driven by several key factors. The primary reason is the increasing demand for polymer excipients in the continuously developing pharmaceutical market in the Asia Pacific area. From the cases of China and India, there has been a change in slope regarding the abstraction of pharmaceutical products through the production and consumption of the same due to the increased prevalence of chronic diseases, an aging population, and more access to healthcare. As the industry of manufacturing drugs evolves, the use of polymer excipients, which are crucial in drug formulation, also increases.

This region is experiencing high growth in the demand for generics, boosting the polymer excipients market. Today's generic drug makers depend mostly on excipients to make their products safe and effective for their users. Polymer excipients are well accepted in this large and emerging market because of their advantages in terms of improved stability and bioavailability of generic drugs.

The increasing trend of personalized medications, along with the advances in new drug delivery systems in the Asia Pacific region, have boosted the polymer excipients market. Because of their flexibility in the composition of drug formulations, polymer excipients have good potential for meeting the existing and emerging market needs in this region.

In addition, the growth of the biopharmaceutical sector and the invention of the COVID-19 vaccine in the Asia Pacific region have also increased the application of excipients in manufacturing life-saving medicines. This has helped bring several improvements in the polymer excipients market because producers expand their concerns on research to conform to the ever-growing market. Owing to these factors, the Asia Pacific area leads the polymer excipients market within the forecast period because of the fast-growing pharmaceutical industry, the increasing scope of generics, individualized medications, and the advancement of new drug delivery systems.

The polymer excipients market is segmented and analyzed as follows:

By Product Type

  • Polyvinylpyrrolidone
  • Polyethylene Glycol
  • Starch
  • Micro Crystalline Cellulose (MCC)
  • Ethyl and Methyl Cellulose
  • Hydroxypropyl Methylcellulose (HPMC)
  • Others

By Application

  • Binders
  • Viscosity Modifiers
  • Coatings
  • Flavors
  • Preservatives
  • Colorants
  • Sweeteners
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Middle East and Africa
  • Saudi Arabia
  • Saudi Arabia
  • United Arab Emirates
  • Rest of the Middle East and Africa
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Rest of Asia-Pacific

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
    • 4.1.1. Growing Pharmaceutical Industry
    • 4.1.2. Rising Demand for Polymer Excipients from Coatings Application
  • 4.2. Market Restraints
    • 4.2.1. Stringent Rules by Regulatory Bodies
    • 4.2.2. Concerns to Meet the Required Quality of Product
    • 4.2.3. Threats from Substitutes
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. POLYMER EXCIPIENTS MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Polyvinylpyrrolidone
  • 5.3. Polyethylene Glycol
  • 5.4. Starch
  • 5.5. Micro Crystalline Cellulose (MCC)
  • 5.6. Ethyl and Methyl Cellulose
  • 5.7. Hydroxypropyl Methylcellulose (HPMC)
  • 5.8. Others

6. POLYMER EXCIPIENTS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Binders
  • 6.3. Viscosity Modifiers
  • 6.4. Coatings
  • 6.5. Flavors
  • 6.6. Preservatives
  • 6.7. Colorants
  • 6.8. Sweeteners
  • 6.9. Others

7. POLYMER EXCIPIENTS MARKET BY GEOGRAPHY

  • 7.1. Global Overview
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Rest of South America
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Rest of Europe
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. United Arab Emirates
    • 7.5.3. Rest of Middle East and Africa
  • 7.6. Asia-Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Taiwan
    • 7.6.6. Thailand
    • 7.6.7. Indonesia
    • 7.6.8. Rest of Asia-Pacific

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. ABITEC
  • 9.2. ADM
  • 9.3. Ashland
  • 9.4. BASF SE
  • 9.5. Cargill, Incorporated.
  • 9.6. Colorcon
  • 9.7. Croda International Plc
  • 9.8. DFE Pharma
  • 9.9. Dow
  • 9.10. DuPont
  • 9.11. Eastman Chemical Company
  • 9.12. Evonik Industries AG
  • 9.13. FINAR LIMITED
  • 9.14. JRS PHARMA
  • 9.15. Kerry Inc.
  • 9.16. Roquette Freres
  • 9.17. The Lubrizol Corporation
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦